News | Radiation Therapy | February 03, 2016

Radioactive Medicine Markets Poised for Double-digit Growth

Nuclear medicine, proton therapy and brachytherapy expected to grow more than twice as fast as total global health expenditures to 2030

MEDraysintell, nuclear medicine, proton therapy, brachytherapy, global markets, 2030

February 3, 2016 — The nuclear medicine, proton therapy and brachytherapy markets represent less than 0.1 percent of global health expenditures but are expected to grow more than twice as fast, according to a new report from MEDraysintell.

Global health expenditures reached some $7.4 billion in 2014 and should grow by 3-4 percent per year to 2030. The nuclear medicine, proton therapy and brachytherapy markets reached about $5.8 billion in 2014 and are expected to grow by 10-11 percent annually to 2030. There is an increasing interest from investors and industry as new technologies and products are being marketed or under development.

The global nuclear medicine market is expected to reach $24 billion by 2030, showing an annual average growth of 11 percent, with radiotherapeutics being key drivers of this growth. The number of operational medical cyclotrons is also expected to grow with the emergence of the Asian and South American markets and the need of tools for new proprietary tracers.

The global proton therapy market saw record sales orders at just over $1 billion in 2015, more than twice as much as in 2014.

The global market for brachytherapy is expected to grow by 8 percent a year to 2030, mainly driven by microspheres and electronic brachytherapy and with the low-dose rate (LDR) brachytherapy seeds market mainly growing in emerging regions.

For more information: www.medraysintell.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
New U.S. Tariffs on Chinese Goods Include Imaging Equipment
News | Radiology Business | June 15, 2018 | Jeff Zagoudis, Associate Editor
The Office of the U.S. Trade Representative (USTR) released the much-anticipated list of Chinese-manufactured goods...
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
FDA Releases New Report Assessing Quality, Safety and Effectiveness of Medical Device Servicing
News | Radiology Business | June 07, 2018
A new report from the U.S. Food and Drug Administration (FDA) discusses the continued quality, safety and effectiveness...
Overlay Init